TNF alpha
PreclinicalBiologic
TNF alpha is one of 6 biologic programs targeting Central Nervous System. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Central Nervous System
#DrugCompanyPhaseTrials
1Imuran
LLegacy Health System
Phase 3
Furmonertinib
AAllist Pharmaceuticals, Inc.
Phase 2
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Salbutamol
GSKPreclinical
Endotoxin
UUniversity of California, Los Angeles
Preclinical
TNF alpha
CChung Shan Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Central Nervous System1 trial
Ankylosing Spondylitis1 trial
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis
Unknown status·—·Phase 2·NCT02456363·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TNF alpha. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- CChung Shan Medical University